SCHEMBL6316047

SCHEMBL6316047

NC(=O)c1c(-c2cccs2)noc1NC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRD O14764 1/20 0.47
GABRB1 P18505 1/20 0.47
GABRA4 P48169 1/20 0.47
MAPT P10636 6/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HTT P42858 4/20 0.45
LMNA P02545 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
KDM4E B2RXH2 3/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPK1 P28482 2/20 0.43
ALDH1A1 P00352 2/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PTGS1 P23219 4/20 0.42
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316642 0.91 LMNA (0.58) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6316376 0.90 SMN1; SMN2 (0.50) MAPTHTTSMN1; SMN2KDM4EMCOLN3
SCHEMBL6315217 0.90 HTT (0.45) GABRDGABRB1GABRA4MAPTMEN1
SCHEMBL6316781 0.88 TRPV1 (0.45) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6314638 0.88 ALDH1A1 (0.54) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6316533 0.87 ADCY1 (0.54) GABRDGABRB1GABRA4MAPTMEN1
SCHEMBL6318622 0.86 MAPT (0.47) MAPTMEN1KMT2AHTTLMNA
SCHEMBL6323548 0.84 MAPT (0.52) MAPTMEN1KMT2AHTTKDM4E
SCHEMBL6315171 0.84 ADCY1 (0.56) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL6318710 0.84 HDAC1 (0.43) GABRDGABRB1GABRA4MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GABRD 1137/4885GABRB1 951/4885GABRA4 978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.